

INTERIM MONITOR AGREEMENT

This Interim Monitor Agreement (“Monitor Agreement”) entered into effective as of the 10th day of July, 2006, among Francis J. Civile and Watson Pharmaceuticals, Inc., (“Watson” or “Respondent”), provides as follows:

WHEREAS, the United States Federal Trade Commission (the “Commission”), in *In the Matter of Watson Pharmaceuticals, Inc.*, has accepted or will shortly accept for public comment an Agreement Containing Consent Order, incorporating a Decision and Order (the “Order”), which, among other things, requires Respondent to divest or transfer certain defined assets and, to ensure that Respondent complies with its obligations under the Order, provides for the appointment of an Interim Monitor;

WHEREAS, the Commission may appoint Francis J. Civile as such monitor (the “Interim Monitor”) pursuant to the Order to monitor Respondent’s compliance with the terms of the Order and with the Remedial Agreements referenced in the Order, and Francis J. Civile has consented to such appointment;

WHEREAS, the Order further provides or will provide that Respondent shall execute a Monitor Agreement, subject to the prior approval of the Commission, conferring all the rights, powers and authority necessary to permit the Interim Monitor to carry out such duties and responsibilities pursuant to the Order;

WHEREAS, this Monitor Agreement, although executed by the Interim Monitor and Watson, is not effective for any purpose, including but not limited to imposing rights and responsibilities on Respondent or the Interim Monitor under the Order, until it has been approved by the Commission; and

WHEREAS, the parties to this Monitor Agreement intend to be legally bound;

NOW, THEREFORE, the parties agree as follows:

1. Capitalized terms used herein and not specifically defined herein shall have the respective definitions given to them in the Order. The term “Monitored Assets” means the Categorized Assets as defined in the Order.
2. The Interim Monitor shall have all of the powers and responsibilities conferred upon the Interim Monitor by the Order, including but not limited to:
 - a. supervising the divestiture of the Monitored Assets; and
 - b. supervising the performance of any transition services required by the Order.
3. Respondent hereby agrees that it will fully and promptly comply with all terms of the Order requiring them to confer all rights, powers, authority and privileges upon the Interim Monitor, or to impose upon itself any duties or obligations with respect to the Interim Monitor, to enable the Interim Monitor to perform the duties and responsibilities of the Interim Monitor thereunder.

4. Respondent further agrees that:
- a. it will use reasonable best efforts to ensure that the relevant Commission-approved Acquirer(s) of the affected assets enters into an agreement with the Interim Monitor governing the facilitation of the Interim Monitor's duties under the Order and the exchange of information between the Commission-approved Acquirer and the Interim Monitor;
 - b. no later than ten (10) Business Days after the Commission approves this Monitor Agreement, it will provide the Interim Monitor with the following, as applicable:
 - (1) a copy of the Remedial Agreements (or drafts thereof) relating to the Monitored Assets, including any exhibits, schedules and appendices;
 - (2) offering or information memoranda, or similar documents and information, provided to the Commission-approved Acquirer(s) relating to the sale of the Monitored Assets;
 - (3) copies of correspondence with, and written reports or minutes of meetings of all substantive contacts and discussions with, any Commission-approved Acquirer(s) relating to the Monitored Assets or Remedial Agreements; and
 - (4) an inventory and description of the Monitored Assets, including a complete inventory of any existing FDA approvals and pending FDA approvals for the Products included in the Monitored Assets and identifying the person(s) responsible for taking such actions as are required to maintain or complete such approvals;
 - c. it will designate a senior individual as a primary Contact for the Interim Monitor and provide a written list of the principal individuals to be involved in the transitioning of the Monitored Assets to the Commission-approved Acquirer(s), together with their locations, telephone numbers, electronic mail address, and responsibilities, and will provide the Interim Monitor with written notice of any changes in such personnel occurring thereafter;
 - d. it will use their reasonable efforts to provide the Interim Monitor with prompt notification (but not later than such notification is available to other meeting participants) of significant meetings, including date, time and venue, scheduled after the execution of this Monitor Agreement, relating to the manufacture, registration, regulatory approvals, marketing, sale and divestiture of the Monitored Assets, and such meetings may be attended by the Interim Monitor or his representative, at the Interim Monitor's option or at the request of the Commission or staff of the Commission;
 - e. it will provide the Interim Monitor with the minutes, if any, of the above-referenced meetings as soon as practicable and, in any event, not later than those

minutes are available to any employee of the Respondent other than Respondent's attorneys;

- f. it will provide the Interim Monitor with all correspondence, meeting minutes, telephone summaries, reports, sent to or received from the FDA after the execution of this Monitor Agreement relating to the Monitored Assets, and will provide prompt notice of any and all meetings or communications with the FDA relating to or affecting the Monitored Assets;
- g. it will provide the Interim Monitor with electronic or hard copies, as may be appropriate, of all reports submitted to the Commission pursuant to the Order, simultaneous with the submission of such reports to the Commission;
- h. to the extent not reflected in the reports submitted to the Commission pursuant to the Consent Agreement and the Order, it will provide every (3) months commencing one (1) month after the Consent Agreement is accepted by the Commission for public comment, or as requested by the Interim Monitor, full and detailed electronic or hard copy reports to the Interim Monitor as to all of Respondents' activities and obligations under the Order concerning the Monitored Assets including, without limitation to the extent applicable:
 - (1) all activities concerning the assistance, advice and consultation provided to any Commission-approved Acquirer generally as provided in the relevant Paragraphs of the Order;
 - (2) as applicable, all activities concerned with the manufacture, supply and technology transfer of the Products, including, without limitation, negotiation and operation of supply agreements, actual supply and inventory; and
 - (3) as applicable, all minutes and records of meetings, action plans, and follow-ups to actions plans and meetings, with the Commission-approved Acquirer(s) related to the manufacture, supply, and technology transfer of the Products and, upon request Respondents shall provide the Interim Monitor with any records exchanged at such meetings, or such other records that the Interim Monitor may reasonably require relating to the manufacture, supply, and technology transfer of the Products;

provided however, that, at the time the Order becomes final, the reports described in this paragraph shall be due to the Interim Monitor either as requested by the Interim Monitor or within five (5) Business Days of the date that Respondent files its reports with the Commission as required pursuant to the relevant provision(s) of the Order;

- i. it will comply with the Interim Monitor's reasonable requests for onsite visits of Respondent's facilities (or any contract manufacturer's facility) used to manufacture the Products; and

- j. it will comply with the Interim Monitor's reasonable requests for follow-up discussions or supplementary information concerning any reports provided to or requested by the Interim Monitor pursuant to this Agreement, including, as applicable: meetings and discussions with the principal staff involved in any activities relating to the research, development, manufacture, sale and or divestiture of the Monitored Assets or any Product comprised therein and, further including, actions necessary to maintain all necessary FDA approvals to manufacture and sell any of the Products in the United States and to prevent the destruction, removal, wasting, deterioration or impairment of the Monitored Assets, and will provide the Interim Monitor with access to and hard copies of all other data, records or other information that the Monitor reasonably believes are necessary to the proper discharge of his responsibilities under the Order.
5. Respondent shall promptly notify the Interim Monitor of any significant written or oral communication that occurs after the date of this Monitor Agreement between the Commission and Respondent related to the Order or this Monitor Agreement, together with electronic or hard copies (or, in the case of oral communications, summaries), as may be requested by the Interim Monitor, of such communications.
6. Respondent agrees that to the extent authorized by the Order, the Interim Monitor shall have the authority to employ, at the expense of the Respondent, and with the consent of Respondent, which will not unreasonably be withheld, such consultants, accountants, attorneys and other representatives and assistants as are reasonably necessary to carry out the Interim Monitor's duties and responsibilities, including but not limited to supervising the transfer of Confidential Business Information.
7. The Interim Monitor shall maintain the confidentiality of all information provided to the Interim Monitor by Respondent. Such information shall be used by the Interim Monitor only in connection with the performance of the Interim Monitor's duties pursuant to this Agreement. Such information shall not be disclosed by the Interim Monitor to any third party other than:
 - a. persons employed by, or working with, the Interim Monitor under this Agreement and who have executed a confidentiality agreement consistent with the provisions of this Monitor Agreement; or
 - b. persons employed at the Commission and working on this matter.
8. The Interim Monitor shall maintain a record and inform the Commission of all persons (other than representatives of the Commission) to whom confidential information related to this Agreement has been disclosed.
9. Upon termination of the Interim Monitor's duties under this Monitor Agreement, the Interim Monitor shall promptly return, at Respondent's expense to Respondent all material provided to the Interim Monitor by Respondent that is confidential to Respondent and that it is entitled to have returned to them under the Order, and shall destroy any material prepared by the Interim Monitor that contains or reflects any confidential information of Respondent. Nothing herein shall abrogate the Interim

Monitor's duty of confidentiality, including the obligation to keep such information confidential for a period of ten (10) years after the termination of this Monitor Agreement;

10. The Interim Monitor shall keep confidential for a period of ten (10) years all other aspects of the performance of his duties under this Monitor Agreement and shall not disclose any confidential or proprietary information relating thereto. To the extent that the Interim Monitor wishes to retain any employee, agent, consultant or any other third party to assist the Interim Monitor in accordance with the Order, the Interim Monitor shall ensure that, prior to being retained, such persons execute a confidentiality agreement in a form agreed upon by the Interim Monitor and Respondent.

For the purpose hereof, information shall not be considered confidential or proprietary to the extent that it is or becomes part of the public domain (other than as the result of any action by the Interim Monitor or by any employee, agent, affiliate or consultant of the Interim Monitor), or to the extent that the recipient of such information can demonstrate that such information was already known to the recipient at the time of receipt from a source other than the Interim Monitor, Respondent, or any director, officer, employee, agent, consultant or affiliate of the Interim Monitor or Respondent, when such source is entitled to make such disclosure to such recipient.

11. Nothing in this Monitor Agreement shall require Respondent to disclose any material or information that is subject to a legally recognized privilege or that Respondent is prohibited from disclosing by reason of law or an agreement with a third party.
12. The Interim Monitor shall not have a fiduciary responsibility to the Respondent, but shall have fiduciary duties to the Commission.
13. Each party shall be reasonably available to the other to discuss any questions or issues that either party may have concerning compliance with the Order as it relates to Respondent.
14. Respondent will pay the Interim Monitor **Non-Public Information** for all reasonable time spent in the performance of the Interim Monitor's duties including all monitoring activities related to the efforts of the Commission-approved Acquirer of the Monitored Assets, all work in connection with the negotiation and preparation of this Monitor Agreement, and all reasonable and necessary travel time. The Interim Monitor's hourly rate should be reviewed and may be adjusted by agreement with Respondents every six months.
 - a. In addition, Respondent will pay (i) all out-of-pocket expenses reasonably incurred by the Interim Monitor in the performance of the Interim Monitor's duties, including any auto, train or air travel (at business class rates for intercontinental air travel) in the performance of the Interim Monitor's duties, international telephone calls, and (ii) all fees and disbursements reasonably incurred by such consultants, accountants, attorneys, investment bankers, business brokers, appraisers, and other representatives and assistants as are reasonably necessary to carry out the Interim Monitor's duties. **Non-Public Information**

Non-Public Information

- b.
 - c.
 - d. The Interim Monitor shall have full and direct responsibility for compliance with all applicable laws, regulations and requirements pertaining to work permits, income and social security taxes, unemployment insurance, worker's compensation, disability insurance, and the like.
15. Respondent hereby confirm its obligation to indemnify the Interim Monitor and hold the Interim Monitor harmless in accordance with and to the extent required by the Order. Respondent shall indemnify the Interim Monitor and any subcontractor and their respective agents, partners, principals, officers and employees (the "Indemnified Parties") and hold the Indemnified Parties harmless (regardless of form of action, whether in contract, statutory law, tort or otherwise) against any losses, claims, damages, liabilities or expenses arising out of or in connection with, the performance of the Interim Monitor's duties and obligations including all reasonable fees of counsel and other reasonable expenses incurred in connection with the preparation for, or defense of, any claim, whether or not resulting in any liability, except to the extent that such losses, claims, damages, liabilities, or expenses result from misfeasance, gross negligence, willful or wanton acts, or bad faith by the Interim Monitor.
16. The Interim Monitor's maximum liability to the Respondent relating to services rendered pursuant to this Agreement (regardless of the form of the action, whether in contract, statutory law, tort, or otherwise) shall be limited to the total sum of the fees paid to the Interim Monitor by Respondent, except to the extent resulting from the misfeasance,

gross negligence, willful or wanton acts, or bad faith by the Interim Monitor or any of his subcontractors, agents, partners, principals, officers or employees, in which case the liability is not so limited.

17. Respondent agree that the Respondent's obligations to indemnify the Interim Monitor extend to any agreement that is entered between the Interim Monitor and any Commission-approved Acquirer and relates to the Interim Monitor's responsibilities under the Monitor Agreement and/or the Order.
18. Upon this Monitor Agreement becoming effective, the Interim Monitor shall be permitted, and Respondent shall be required, to notify all Commission-approved Acquirers of his appointment as Interim Monitor.
19. In the event of a disagreement or dispute between Respondent and the Interim Monitor concerning Respondent's obligations under the Order and, in the event that such disagreement or dispute cannot be resolved by the parties, any party may seek the assistance of the responsible individual in the Commission's Compliance Division to resolve the issue. In the case of any disagreement or dispute between Respondent and the Interim Monitor not relating to Respondent's obligations under the Order, and in the event that such disagreement or dispute cannot be resolved by the parties, the parties shall submit the matter to binding arbitration (before a single arbitrator) before the American Arbitration Association under its Commercial Arbitration Rules. Binding arbitration shall not be available, however, to resolve any disagreement or dispute concerning the Respondent's obligations pursuant to the Order.
20. This agreement shall be subject to the substantive law of the State of New Jersey (regardless of any other jurisdiction's choice of law principles).
21. This Monitor Agreement shall terminate no later then the date set forth in the relevant provision of the Order or the Commission has appointed a substitute monitor pursuant to the Order, provided however, that the Commission may extend this Monitor Agreement as may be necessary or appropriate to accomplish the purposes of the Order. The confidentiality obligations of this Monitor Agreement shall survive its termination.
22. In the event that, during the term of this Monitor Agreement, the Interim Monitor becomes aware that he has or may have a conflict of interest that may affect or could have the appearance of affecting the performance by the Interim Monitor, or persons employed by, or working with, the Interim Monitor, of any duty under this Monitor Agreement, the Interim Monitor shall promptly inform both Respondent and the Commission of such conflict or potential conflict.
23. In the performance of his functions and duties under this Monitor Agreement, the Interim Monitor shall exercise the standard of care and diligence that would be expected of a reasonable person in the conduct of his own business affairs.
24. It is understood that the Interim Monitor will be serving under this Interim Monitor Agreement as an independent contractor and that the relationship of employer and employee shall not exist between Interim Monitor and Watson.

25. This Agreement is for the sole benefit of the Parties hereto and their permitted assigns and the Commission, and nothing herein express or implied shall give or be construed to give any other person any legal or equitable rights hereunder.
26. This Agreement contains the entire agreement between the parties hereto with respect to the matters described herein and replaces any and all prior agreements or understandings, whether written or oral.
27. Any notices or other communication required to be given hereunder shall be deemed to have been properly given if sent by mail or fax (with acknowledgment of receipt of such fax having been received), to the applicable party at its address below (or to such other address as to which such party shall hereafter notify the other party):

If to the Interim Monitor, to:

Francis J. Civile
16 Fox Hill Road
Califon, New Jersey 07830
Telephone: (908) 439-2441
Facsimile: (908) 439-3834
email: fjciville@aol.com

If to Watson:

Watson Pharmaceuticals, Inc.
311 Bonnie Circle
Corona, CA 91720
Attn: General Counsel
Telephone: (951) 493-5300
Facsimile: (951) 493-5821

If to the Commission:

Federal Trade Commission
600 Pennsylvania Avenue, NW
Washington, DC 20580
Attn.: David von Nirschl
Telephone: (202) 326-3213
Facsimile: (202) 326-3396


29. This Monitor Agreement shall not become binding until it has been approved by the Commission and the Order has been accepted for public comment.
30. This Monitor Agreement may be signed in counterparts.

IN WITNESS WHEREOF, the parties hereto have executed this Monitor Agreement as of the date first above written.

Francis J. Civile

Watson Pharmaceuticals, Inc.


By:



Name: David A. Buchen
Title: Senior Vice President,
General Counsel & Secretary

IN WITNESS WHEREOF, the parties hereto have executed this Monitor Agreement as of the date first above written.

Francis J. Civile

A handwritten signature in cursive script that reads "Francis J. Civile". The signature is written in black ink and is positioned above a horizontal line.

Watson Pharmaceuticals, Inc.

By: _____
Name: David A. Buchen
Title: Senior Vice President,
General Counsel & Secretary